Management of Renal Disease

  • Author: Mohamed G. Atta, MD, MPH (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/14/17 (What's New)

Summary

  • Boosted PIs and tenofovir DF have been associated with significant declines in renal function in combination and individually[Goicoechea 2008; Gallant 2009; Morlat 2013]
  • Tenofovir DF should be avoided in patients with eGFR < 60 mL/min/1.73 m2[Lucas 2014]
  • Tenofovir AF is less nephrotoxic than tenofovir DF in clinical trials and is recommended as either preferred over or as an appropriate alternative to tenofovir DF in US guidelines

Action required